Article breakdown
Current reviews in musculoskeletal medicine • 2025 Dec • Vol 18, 611-619. PMID 40789979.
This paper is a review, so it summarizes earlier studies rather than reporting one new experiment. BPC-157 has shown healing-related effects in many animal studies, but human research is very limited. Because there are only a few small human studies and no large rigorous trials, the review says BPC-157 should still be treated as investigational and used cautiously.
In short
This paper is a review, so it summarizes earlier studies rather than reporting one new experiment.
BPC-157 has shown healing-related effects in many animal studies, but human research is very limited.
Because there are only a few small human studies and no large rigorous trials, the review says BPC-157 should still be treated as investigational and used cautiously.
Deep dive
Why This Paper Exists
BPC-157 is becoming more available and popular, especially for healing claims, but it is also controversial from a regulatory standpoint. The authors reviewed the existing evidence to see how strong the science really is for musculoskeletal use.
What The Authors Wanted To Answer
The authors wanted to assess what is known about how BPC-157 might work, whether it may help musculoskeletal healing, and how much safety information exists in animals and humans.
How The Study Was Done
This is a scoping narrative review. It summarizes preclinical and clinical literature on BPC-157 rather than testing the compound in a single new trial. The abstract does not describe detailed search methods or selection criteria.
What The Study Found
The review says BPC-157 has shown regenerative and protective effects in many animal models, including effects linked to blood vessel growth, fibroblast activity, muscle and endothelial repair, neuromuscular stabilization, and reduced inflammation. These effects may be especially relevant in tissues with poor blood supply such as tendons and myotendinous junctions. However, human evidence is sparse: the abstract mentions only three pilot studies, and although no adverse effects were reported there, large high-quality trials are missing.
Takeaway
The authors conclude that BPC-157 looks promising in preclinical research but does not yet have enough human evidence to support confident clinical use. They argue that it should currently be viewed as investigational until well-designed human trials clarify safety and effectiveness.
Limits
This is a review article, so it summarizes prior studies rather than providing one new controlled experiment.
The abstract does not give detailed review methods, such as how studies were searched for or selected.
Human evidence appears extremely limited, with only three pilot studies mentioned in the abstract, so clinical conclusions are uncertain based on the abstract alone.
Key numbers
According to the abstract, only three human studies of BPC-157 were identified, showing how limited the clinical evidence is.
Source abstract
PURPOSE OF REVIEW
This scoping review aims to evaluate the molecular mechanisms, therapeutic potential, and safety concerns of Body Protective Compound-157 (BPC-157) in the context of musculoskeletal healing. Given the compound’s increasing availability, popularity, and its regulatory controversies, we sought to assess the breadth and quality of preclinical and clinical data supporting its use in musculoskeletal medicine.
RECENT FINDINGS
BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demonstrated regenerative properties across numerous animal models. It activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization. It also engages ERK1/2 signaling, facilitates endothelial and muscle repair, and exerts anti-inflammatory effects. These effects promote angiogenesis, fibroblast activity, and neuromuscular stabilization, particularly in poorly vascularized tissues such as tendons and myotendinous junctions. Despite broad preclinical support, human data are extremely limited. Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. No adverse effects were reported, but rigorous, large-scale trials are lacking.
SUMMARY
BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in musculoskeletal medicine. Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available. Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution. This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine.